News and Press Releases
Neurizon Receives Ethics Approval for Phase 1 NUZ-001 Oral Liquid Formulation Study
Bellberry Human Research Ethics Committee (HREC) approves Neurizon’s Phase 1 formulation study supporting development of the NUZ-001 oral liquid formulation and continued advancement of NUZ-001 for amyotrophic lateral sclerosis (ALS)...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 13, 2026
Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Australia
MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.
Vibra to Support Expansion of MindMaze Therapeutics’ Neurorehabilitation Platform across Leading U.S. Health Systems 12 May 2026 -- Geneva, Switzerland and Pennsylvania, US -- MindMaze Therapeutics, a pioneer in advanced...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 12, 2026
MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision Neurotherapeutics in the U.S.
Collaboration targets large provider groups to accelerate adoption of MindMaze Therapeutics’ evidence-based neurotherapeutic platform 30 April 2026 -- Geneva, Switzerland and Pennsylvania, US -- MindMaze Therapeutics, a pioneer in advanced...
Category: Other, Pharmaceutical
Posted: April 30, 2026
U.S. FDA Grants Breakthrough Device Designation to Laguna Diagnostics’ mRNA Gene Biomarker Test to Aid in Differentiation of Schizophrenia and Bipolar I Disorder
29 April 2026 -- California, US -- Laguna Diagnostics, LLC today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s mRNA Gene...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 29, 2026
NICE recommends UCB’s RYSTIGGO▼ (rozanolixizumab) for adults with antibody-positive generalised myasthenia gravis in Final Draft Guidance
Rozanolixizumab, discovered and developed in the UK, has been recommended by NICE as an add on treatment option for eligible adults with antibody-positive generalised myasthenia gravis (gMG) Recommendation represents three...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 29, 2026
IMAAVY (nipocalimab)▼shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained minimal symptom expression (MSE)...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 22, 2026
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Neuland to open commercial peptide facility as part of planned phased expansion
The CDMO’s Module 1 commercial production facility to be operational by summer 2026 9 March 2026 -- Hyderabad, India -- Neuland Laboratories will open its new commercial peptide facility in the...
Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: March 9, 2026
11th Floor (5th Level), Phoenix IVY Building, Plot No. 573A-III, Road No. 82, Jubilee Hills, Hyderabad, 500033, Telangana, India.
FundaMental Pharma to showcase groundbreaking approach to treatment-resistant depression at Bio-Neuroscience Conference
Presentation will highlight lead clinical candidate FMP374, a novel dual-acting NMDAR modulator advancing toward IND-enabling studies for TRD 17 February 2026 -- Heidelberg, Germany -- FundaMental Pharma GmbH, a preclinical-stage...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: February 17, 2026
Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant schizophrenia (TRS) By targeting the hippocampus region of the brain, evenamide...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 3, 2026
MetP Pharma’s Neural Targeting Drug Delivery Technology Sets a New Benchmark for Brain Delivery of Peptides
Intranasal nose-to-brain delivery achieves superior brain exposure with low systemic burden, outperforming transporter-based BBB technologies in preclinical studies 29 January 2026 -- Emmetten, Switzerland -- MetP Pharma AG, a pioneer...
Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: January 29, 2026
Schynweg 7 Office: St. Anna-Weg 16 P.O.Box 138 6376 Emmetten / Switzerland
Bial Achieves Key Milestone in Phase 2b ACTIVATE Study ofBIA 28-6156 in GBA1-Associated Parkinson’s Disease
75% of patients have completed the Week 78 Last Study Visit Topline results expected in mid-2026 27 January 2026 -- Porto, Portugal -- Bial, an innovation-driven biopharmaceutical company focused on...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 27, 2026
Journal of Prevention of Alzheimer’s Disease publishes trial results showing HMTM potentially offers accessible oral treatment option for patients with early Alzheimer’s disease
26 January 2026 -- Scotland, UK -- TauRx Therapeutics Management Ltd today announced results from its Phase III LUCIDITY trial evaluating the efficacy and safety of hydromethylthionine mesylate (HMTM) in...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 26, 2026
MetP Pharma’s Enabling Technology Creates a New Brain-Targeted GLP-1 Opportunity
Preclinical data in rats demonstrate dose-dependent and rapid brain targeting of intranasal semaglutide with low systemic exposure 22 January 2026 -- Emmetten, Switzerland -- MetP Pharma AG, a pioneer in nose-to-brain...
Category: Biotechnology, Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: January 22, 2026
Schynweg 7 Office: St. Anna-Weg 16 P.O.Box 138 6376 Emmetten / Switzerland
Meeting with Two Scientific Poster Presentations and Hot Topic Presentation
16 January 2026 -- New York, US -- AtaiBeckley Inc, a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments,...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 16, 2026
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
Issued and pending claims expected to protect ALTO-207 into the mid-2040s 14 January 2026 -- California, US -- Alto Neuroscience, Inc, a clinical-stage biopharmaceutical company focused on the development of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2026
